Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
Champions Oncology (NASDAQ:CSBR) has announced that seventeen abstracts have been accepted for presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, scheduled for April 25-30, 2025.
The presentations will showcase the company's research in multiple areas, including:
- Innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing
- AI-driven models using multi-omics datasets for patient outcome prediction
CEO Ronnie Morris highlighted that these presentations demonstrate how Champions' proprietary PDX bank and multi-omics dataset are advancing oncology research and supporting biopharma partners in accelerating drug development.
Champions Oncology (NASDAQ:CSBR) ha annunciato che diciassette abstract sono stati accettati per la presentazione al 2025 American Association for Cancer Research (AACR) Annual Meeting a Chicago, previsto per il 25-30 aprile 2025.
Le presentazioni metteranno in mostra la ricerca dell'azienda in diverse aree, tra cui:
- Piattaforme innovative in vivo e organoidi per il testing di farmaci in oncologia e immuno-oncologia
- Modelli guidati dall'IA che utilizzano dataset multi-omici per la previsione degli esiti dei pazienti
Il CEO Ronnie Morris ha sottolineato che queste presentazioni dimostrano come la banca PDX proprietaria e il dataset multi-omico di Champions stiano avanzando la ricerca oncologica e supportando i partner biopharma nell'accelerare lo sviluppo dei farmaci.
Champions Oncology (NASDAQ:CSBR) ha anunciado que diecisiete resúmenes han sido aceptados para presentación en la Reunión Anual de la Asociación Americana para la Investigación del Cáncer (AACR) 2025 en Chicago, programada del 25 al 30 de abril de 2025.
Las presentaciones mostrarán la investigación de la empresa en múltiples áreas, incluyendo:
- Plataformas innovadoras in vivo y organoides para pruebas de medicamentos en oncología e inmuno-oncología
- Modelos impulsados por IA que utilizan conjuntos de datos multi-ómicos para la predicción de resultados en pacientes
El CEO Ronnie Morris destacó que estas presentaciones demuestran cómo el banco PDX propietario y el conjunto de datos multi-ómico de Champions están avanzando la investigación en oncología y apoyando a los socios biopharma en la aceleración del desarrollo de medicamentos.
챔피언스 온콜로지(나스닥:CSBR)는 2025년 미국 암 연구 협회(AACR) 연례 회의에서 발표할 17개의 초록이 수락되었다고 발표했습니다. 이 회의는 2025년 4월 25일부터 30일까지 시카고에서 개최될 예정입니다.
발표에서는 회사의 여러 분야에 대한 연구를 선보일 예정이며, 포함된 내용은 다음과 같습니다:
- 온콜로지 및 면역온콜로지 약물 테스트를 위한 혁신적인 인 비보 및 오르가노이드 플랫폼
- 환자 결과 예측을 위한 다중 오믹스 데이터세트를 사용하는 AI 기반 모델
CEO 로니 모리스는 이러한 발표가 챔피언스의 독점 PDX 은행과 다중 오믹스 데이터세트가 온콜로지 연구를 발전시키고 생명공학 파트너들이 약물 개발을 가속화하는 데 어떻게 기여하고 있는지를 보여준다고 강조했습니다.
Champions Oncology (NASDAQ:CSBR) a annoncé que dix-sept résumés ont été acceptés pour présentation lors de la Réunion Annuelle de l'Association Américaine pour la Recherche sur le Cancer (AACR) 2025 à Chicago, prévue du 25 au 30 avril 2025.
Les présentations mettront en avant les recherches de l'entreprise dans plusieurs domaines, notamment :
- Des plateformes innovantes in vivo et organoïdes pour le test de médicaments en oncologie et en immuno-oncologie
- Des modèles pilotés par l'IA utilisant des ensembles de données multi-omiques pour la prédiction des résultats des patients
Le PDG Ronnie Morris a souligné que ces présentations montrent comment la banque PDX propriétaire et l'ensemble de données multi-omique de Champions avancent la recherche en oncologie et soutiennent les partenaires biopharmaceutiques dans l'accélération du développement de médicaments.
Champions Oncology (NASDAQ:CSBR) hat angekündigt, dass siebzehn Abstracts zur Präsentation auf dem 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago akzeptiert wurden, das vom 25. bis 30. April 2025 stattfinden wird.
Die Präsentationen werden die Forschung des Unternehmens in mehreren Bereichen zeigen, darunter:
- Innovative In-vivo- und Organoid-Plattformen für die Testung von Arzneimitteln in der Onkologie und Immunonkologie
- KI-gesteuerte Modelle, die Multi-Omics-Datensätze zur Vorhersage von Patientenergebnissen nutzen
CEO Ronnie Morris hob hervor, dass diese Präsentationen zeigen, wie die proprietäre PDX-Bank und der Multi-Omics-Datensatz von Champions die Onkologieforschung vorantreiben und Biopharma-Partner dabei unterstützen, die Arzneimittelentwicklung zu beschleunigen.
- Acceptance of 17 research abstracts at major industry conference demonstrates strong R&D pipeline
- Company showcasing advanced technological capabilities in AI and multi-omics data analysis
- Continued development of proprietary PDX bank strengthens competitive position
- None.
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes.
"We are excited to present our latest research at AACR 2025, demonstrating how Champions' proprietary PDX bank and unparalleled multi-omics dataset are driving innovation in oncology research", said Ronnie Morris, MD, CEO of Champions Oncology, "these findings reinforce our ability to support biopharma partners in accelerating the path from target discovery to clinical success."
For a full list of posters and presentation details, visit Champions Oncology at AACR 2025. To schedule a meeting with the Champions team during AACR 2025, please visit the same link.
About Champions Oncology
Champions Oncology is a global preclinical and clinical specialty testing services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
How many abstracts will Champions Oncology (CSBR) present at AACR 2025?
What research areas will CSBR showcase at AACR 2025?
When and where is Champions Oncology (CSBR) presenting at AACR 2025?
What proprietary technologies will CSBR highlight at AACR 2025?
